Jim Mellon is a British entrepreneur and investor with a wide range of interests. Through his private investment company, Burnbrae Group, he has substantial real estate holdings in Germany and the Isle of Man, as well as holdings in private and public companies. Jim’s investment philosophy is underpinned by his ability to recognise emerging trends that give rise to new industries or major shifts in markets. More recently Jim has established himself as a leader in the nascent field of ageing research and longevity. His groundwork into the field is summarised in the book Juvenescence which he also co-authored. For decades, scientists have quietly been working away to understand the fundamental mechanisms of ageing. As a result of this progress, scientists have been reproducibly altering the rates of ageing and maximum lifespan in animal models. These discoveries are being translated into humans and will soon give rise to the largest industry on the planet. Jim and his partners have now set up Juvenescence, a company developing therapies for ageing and the diseases of ageing, to capitalise on this money fountain. Jim sits on the Board of Trustees of the Buck Institute for Research on Aging, and the American Federation for Aging Research (AFAR). He is also a trustee of Lifeboat Foundation, is an Honorary Fellow of Oriel College at the University of Oxford and sits on the Advisory Board of the Milken Institute’s Centre for the Future of Aging. Jim has been honoured by the AFAR with the George E. and Marie J. Doty Award for his support of ageing research.
